279 related articles for article (PubMed ID: 30994985)
1. [Bone effects of bisphosphonates and denosumab treatments in breast or prostate cancer].
Biver E
Rev Med Suisse; 2019 Apr; 15(647):824-830. PubMed ID: 30994985
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. Bone health during endocrine therapy for cancer.
Rachner TD; Coleman R; Hadji P; Hofbauer LC
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies].
Todenhöfer T; Schwentner C; Schilling D; Gakis G; Stenzl A
Urologe A; 2011 Sep; 50(9):1055-63. PubMed ID: 21744161
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
8. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
9. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.
Takahashi S
J Bone Miner Metab; 2023 May; 41(3):307-316. PubMed ID: 37036530
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases and bone loss medical treatment in prostate cancer patients.
Safriadi F
Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of RANK ligand to treat bone metastases].
Body JJ
Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
[TBL] [Abstract][Full Text] [Related]
14. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Miller K; Steger GG; Niepel D; Lüftner D
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
[TBL] [Abstract][Full Text] [Related]
16. Managing Bone Health in Breast Cancer.
Kearns AE
Endocr Pract; 2023 May; 29(5):408-413. PubMed ID: 36509360
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for cancer-related bone loss.
Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
[TBL] [Abstract][Full Text] [Related]
18. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
19. Screening for osteoporosis after breast cancer: for whom, why and when.
Trémollieres FA
Maturitas; 2014 Nov; 79(3):343-8. PubMed ID: 25308162
[TBL] [Abstract][Full Text] [Related]
20. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
Hayes AR; Brungs D; Pavlakis N
PLoS One; 2018; 13(1):e0191455. PubMed ID: 29370211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
